Drug Trial Radar · NCT04972292
Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar Extraction
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Nov 8, 2023
Primary completion
May 28, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical, multicenter, randomized, parallel-group, double-blind, double-dummy, comparative study of non-inferiority. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Conditions
- Pain
Interventions
FDC of codeine 30 mg/dipyrone 500 mgDrug
Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
TylexDrug
Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- sum of pain relief scores over 6 hours (TOTPAR6)Time frame: 6 hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eurofarma Laboratórios S.A
Brasil, São Paulo, Brazil
Eurofarma Laboratorios S.A
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.